Inify Laboratories enter a research partnership with the Department of Molecular Medicine and Surgery at Karolinska Institutet aiming to advance precision diagnostics within prostate cancer
STOCKHOLM – November 05, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, is proud to announce a partnership with the ProMort research team at Karolinska Institutet, aimed at transforming prostate cancer diagnostics. The primary objective of this collaboration is to improve the precision of prostate cancer diagnosis through AI-driven image analysis.
“When our ProMort team started the discussions with Inify, we quickly realized the power of their organization and technology. A collaboration has great potential to further advance the important work of identifying markers to determine the degree of malignancy in prostate cancer, while also maintaining a high and consistent quality. I am delighted with this partnership and look forward to combining great AI models with talented people", says Olof Akre, Professor of Oncological Surgery at the Department of Molecular Medicine and Surgery at Karolinska Institutet.
The ProMort program is a multi-disciplinary, international research project aiming to develop new, high-performing prognostic tools for prostate cancer that can be implemented in clinical practice and help tailoring the right treatment to the right patient. It aims to:
- identify molecular factors associated with prostate cancer death, using tumor tissue from diagnostic biopsies
- identify novel histopathological features associated with prostate cancer death using standard pathological review and artificial intelligence (AI)
- improve prognostication in prostate cancer by combining clinical variables with the outcomes of aims 1-2 in a new prognostic tool.
During the project, Inify’s AI development platform will be used to annotate different prostate cancer growth patterns with focus on cribriform structures, perineural invasion and reactive stroma. This will be used as an input to train AI models that can accurately identify and outline these structures and thereby speed up the diagnostic process as well as laying the foundation for a more streamlined result with less intra- and interobserver variation.
“The project is aligned with our vision to advance precision diagnostics within prostate cancer, and we are excited for the collaboration with such a reputable research group at Karolinska Institutet”, says CEO Fredrik Palm at Inify Laboratories.
“The ultimate ground truth for training diagnostic AI applications is patient outcome. This research project presents a unique opportunity to find hitherto undetected or unverified correlations between histopathological features and patient outcomes. We are proud to contribute to this important project that is very much in line with Inify’s own research strategy”, comments Arto Järvinen, CTO, Inify Laboratories.
For more information, contact CEO Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com.
###
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.
Tags: